Fig. 1
From: The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid

Charged residues in the extracellular roof are critical for ABCG2 function. Mutational analysis of residues in the putative extracellular membrane interface. Charged residues located in the ECL1, ECL2, re-entry helix, and ECL3 were subjected to mutational analysis: a Predicted membrane topology of extracellular regions in the human ABCG2 transporter. Re-entry helix is highlighted in light blue box; consensus glycosylation site is at N596. Residues subjected to mutagenesis are indicated; positively charged residues (blue); negatively charged residues (red). b Immunodetection of ABCG2 mutant variants using the monoclonal anti-ABCG2 (BXP-21) antibody. Mature wild-type (WT) protein migrates at ~72 kDa, the immature unglycosylated bands migrate just below. β-Actin was used as an internal loading control. c Odyssey-based quantification of immunoblots from several independent experiments (n = 3–15). Mature ABCG2 and β-actin bands are shown, and ABCG2 signals were individually normalized to β-actin and represented as the percentage of WT control. d Mitoxantrone efflux is shown for HEK293 cells expressing ABCG2 variants after incubation at 37 °C for 20 min in the presence and absence of the ABCG2 inhibitor Ko143. Ko143-sensitive mitoxantrone efflux is represented as percentage relative to the WT control. Data are from several independent experiments (n = 3–9). All data are shown as means ± SEM. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.1 vs. empty plasmid-transfected HEK293 control (mock). Gray dots refer to values from each independent experiment. e Membrane localization of GFP-tagged ABCG2 variants. GFP signals of GFP-ABCG2 (green) were recorded in a confocal microscopy as described in Methods. DAPI was used to stain the nuclei (blue). Microscopy data are from duplicate experiments. Scale bars in microscopy images correspond to 20 µm.